Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients.
Randomized trial of TAS-102 for refractory metastatic colorectal cancer
TAMPELLINI, MARCO
2015-01-01
Abstract
Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Mayer TAS 102 NEJM 2015.pdf
Accesso riservato
Descrizione: Articolo principale
Dimensione
589.73 kB
Formato
Adobe PDF
|
589.73 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
